Cost offset of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease

References

• American Heart Association. 2004 Heart and stroke statistical update. Dallas, TX, USA. American Heart Association (2004).
   Google Scholar
• American Heart Association. 2003 Heart and stroke statistical update. Dallas, TX, USA. American Heart Association (2003).
   Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the multiple risk factor intervention trial. Prev. Med. 15, 254–273 (1986).
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trials Results. I: reduction in incidence of coronary heart disease. JAMA 251, 351–364 (1984).
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trials Results. II: the relationship of reduction in incidence of coronary heart disease to cholesterol-lowering. JAMA 251, 365–374 (1984).
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study. Lancet 344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. N. Engl. J. Med. 335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• The long term intervention with pravastatin in ischemic disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis M et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol level: results of AFCAPS/TexCAPS. JAMA 279, 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Sheperd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301–1307 (1995).
   PubMedGoogle Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA 279(18), 1458–1462 (2002).
   Google Scholar
• Jackevicius CA, Mamdani M, Tu JV. Adherence to statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288(4), 462–467 (1998).
   Google Scholar
• Benner JS, Glynn RJ, Mogun H et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288(4), 455–461 (2002).
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Di Martino M, Saragoni S et al. Pharmacoutilization of statin therapy after acute myocardial infarction. A real practice analysis based on administrative data. Ital. Heart J. 5(2), 120–126 (2004).
   PubMedGoogle Scholar
• EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur. Heart J. 18(10), 1569–1582 (1997).
   PubMed Web of Science ®Google Scholar
• EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur. Heart J. 22(7), 554–572 (2001).
   PubMed Web of Science ®Google Scholar
• Hughes DA, Bagust A, Haycox A et al. Accounting for noncompliance in pharmacoeconomic evaluations. PharmacoEconomics 19(12), 1185–1197 (2001).
   PubMed Web of Science ®Google Scholar
• Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. PharmacoEconomics 15(3), 217–228 (1999).
   PubMed Web of Science ®Google Scholar
• Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur. Heart J. 17(Suppl. A), 8–15 (1996).
   PubMed Web of Science ®Google Scholar
• Anatomic Therapeutical Chemical Classification. L’Informatore Farmaceutico. 59th Edition. Organizzazione Editoriale Medico Farmaceutica, Milan, Italy (1999).
   Google Scholar
• International Classification of Diseases – 9th Revision. World Health Organization, Geneva, Switzerland (1977).
   Google Scholar
• DRGs and healthcare. In: The Management of Case Mix. Bardsley M, Coles J, Jenkins L (Eds). King Edward’s Hospital Fund, London, UK (1987).
   Google Scholar
• SPSS Inc. for Windows version 11.5. Chicago, IL, USA (2002).
   Google Scholar
• Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Br. Med. J. 321, 1–5 (2000).
   Google Scholar
• Motheral BR, Fairman KA. The use of claims databases for outcome research: rational challenges and strategies. Clin. Ther. 19(2), 346–366 (1998).
   Google Scholar
• Relman AS. Assessment and accountability. The third revolution in medical care. N. Engl. J. Med. 319(18), 1220–1222 (1997).
   Google Scholar